Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer with a change in the ROS1 gene.
- You are either 70 years or older, or your doctor rates your daily activity level as 2 or higher on a scale called ECOG (meaning you need more help with daily tasks).
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- If you have had chemotherapy or immunotherapy before, a brief waiting period is needed before starting repotrectinib.
- If you have never had a ROS1-targeted drug before, you can join; if you have had one, only some patients qualify.
- You must have adequate kidney, liver, and blood cell counts as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill called repotrectinib for people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The drug aims to shrink brain tumors and control the cancer, especially when brain-focused treatments like surgery or radiation are not needed right away.
This trial is a safety follow-up study for people who are already being treated with repotrectinib in Korea. It looks at how well the drug works and what side effects may occur in patients with ROS1-positive lung cancer or NTRK-positive solid tumors.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This study tests the drug taletrectinib in people with advanced non-small cell lung cancer that has a specific genetic change called ROS1. It is for those who have already tried the drug entrectinib and their cancer progressed. The study aims to see how well taletrectinib works in the real world.
This trial provides access to repotrectinib, a targeted therapy for certain cancers, when no other treatment options are available. It aims to give patients a chance to try this medication under a special program.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.